Navigation Links
Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
Date:6/8/2009

xantrone in particular including, without limitation, the potential failure of pixantrone to prove safe and effective for treatment of relapsed aggressive NHL as determined by the FDA, the failure of pixantrone to have a low cardiotoxicity profile or to produce low cardiac toxicity, the failure of pixantrone to produce high rates of overall response including high rates of complete responses , the company's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    E: deramian@ctiseattle.com
    www.CellTherapeutics.com/press_room

    Investors Contact:
    Ed Bell
    T: 206.282.7100

    Lindsey Jesch Logan
    T: 206.272.4347
    F: 206.272.4434
    E: invest@ctiseattle.com
    www.CellTherapeutics.com/investors

    Medical Information Contact:
    T: 800.715.0944
    E: info@askarm.com


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
3. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
4. Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
5. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
6. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
7. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
8. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
9. Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkins Lymphoma Trial
10. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
11. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 Sanomedics International Holdings, Inc. (OTCQB: ... Global Research & Data Services, demand for thermometers is ... through 2018, as demand for more accurate digital thermometers ... the world,s largest market for thermometers, and one of ... Sanomedics International Holdings, Inc. Sanomedics International Holdings ...
(Date:10/22/2014)... , Oct. 22, 2014  Recently published clinical ... bolstered the already substantial database of evidence. This data ... of Stretta therapy for sufferers of refractory ... clinical evidence supporting Stretta therapy as a safe ... that make Stretta therapy available to nearly 50 million ...
(Date:10/20/2014)... -- Indianapolis interventional medical device maker NICO Corporation ... visualization leader Synaptive Medical announced today ... that they have joined forces to integrate their ... the first of its kind and will make ... BrainPath® interventional access technology and Synaptive,s BrightMatter™ real-time ...
Breaking Medicine Technology:Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5
... April 27, 2007 — SciClone,Pharmaceuticals, Inc. (NASDAQ: SCLN) ... for the Annual Meeting of,the American Society of ... , ,ZADAXIN® (thymalfasin, thymosin alpha 1) Poster,Presentation ... on,Thymosin alpha 1 (T?1) plus Dacarbazine (DTIC) with ...
... Scientific evidence,increasingly links arterial calcification to the ... some scientists question,whether a nanoparticle can live ... in,causing disease. , ,A new Mayo Clinic ... near plaque-filled arteries in animal models. The,study ...
Cached Medicine Technology:SciClone Announces ZADAXIN and SCV-07 Abstracts Accepted at ASCO 2Evidence of Nanoparticles Found in Plaque-Filled Arteries 2
(Date:10/22/2014)... On Saturday, October 25, 2014, the Brownsville ... health and fitness fair ¡Vive tu vida! Get Up! Get ... nutrition for better health and wellness for people of all ... open to the public, will be held at Dean Porter ... to 1:00 pm. , “¡Vive tu Vida! Get Up! ...
(Date:10/22/2014)... 2014 Medical Solutions , ... happy to announce that our co-founder and CFO, ... Analysts’ Staffing 100 for 2014. Anderson was also ... influential people in the staffing industry,” in 2013.     ... 13th-largest healthcare staffing company in the U.S., was ...
(Date:10/22/2014)... October 22, 2014 For Dr. Iris Hunter, ... money; it’s an extension of her life’s mission. Her extensive ... as the owner of FirstLight HomeCare, make it clear that ... to me that my work makes a difference in the ... entrepreneurial spirit, so after much research, I felt ready to ...
(Date:10/22/2014)... TUESDAY, Oct. 21, 2014 (HealthDay News) -- The ... passengers arriving from Ebola-affected nations of West Africa ... screen them for infection with the virus. ... Jeh Johnson noted that 94 percent of air ... land at one of these five airports -- ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 The ... , which is dedicated to distribute health information ... healthcare delivery worldwide announced the development of six ... patients expect when receiving healthcare. These are an ... patient-centered care: “providing care that is respectful of ...
Breaking Medicine News(10 mins):Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 3Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2
... nano-sensor for better detection of Mad Cow Disease agent, ... food safety, researchers in New York are reporting development ... of the deadly prion proteins that cause Mad Cow ... detects binding of prion proteins by detecting frequency changes ...
... Suracell,s Italian partner, DNA Research, officially launches Suracell ... international markets expected to open soon, SOUTH ... ), the leading provider of genetically directed,personalized age ... in,a series of worldwide partnerships to bring its ...
... Palomar Medical,Technologies, Inc. (Nasdaq: PMTI ), ... cosmetic treatments, earlier today announced that,it has entered ... &,Gamble Company (NYSE: PG ) to exploit ... new agreement, P&G retains a non-exclusive,license in the ...
... New streamlined pre-application process helps make sale of long-term care ... insurance ... Treaty Network,America Insurance Company (NYSE: PTA ) has developed ... determine whether,their clients qualify for long-term care insurance (LTCi)., ...
... Environment and Health & Beauty Get a New ... HowToDoThings.com, a,popular online destination that helps solve ... on diverse topics, celebrates the,world,s most popular bean ... in recognition of "Caffeine Awareness Month" in March.,HowToDoThings.com ...
... New information about food,and diet appears every day. ... personal endorsement of a trendy diet, news reports,about conflicting ... how do you,separate the truth from the fiction when ... Month(R), the American Dietetic Association,urges consumers to look beyond ...
Cached Medicine News:Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 2Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 3Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 4Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 5Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 6Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 7Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 8Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 9Health News:Anti-Aging/Genetic Health Leader Suracell, Inc. Expands Internationally 2Health News:Palomar Seeks to License Additional Companies to Home-Use Light-Based Hair Removal Technology 2Health News:Palomar Seeks to License Additional Companies to Home-Use Light-Based Hair Removal Technology 3Health News:Palomar Seeks to License Additional Companies to Home-Use Light-Based Hair Removal Technology 4Health News:Penn Treaty Introduces LTCi QuickPass(SM) Program 2Health News:HowToDoThings.com Brews Up New Uses for Coffee That Will Perk You Up in Recognition of March's 'Caffeine Awareness Month' 2Health News:During National Nutrition Month and Beyond, Find the Facts on Nutrition by Focusing on the Science 2
Unipolar Ventricular Lead...
The Petite leads are low profile (4.8F lead body diameter) implantable endocardial pacing leads which are manufactured using a new proprietary hexafilar coil for permanent stimulation of the ventricl...
Steroid-eluting, screw-in pacing lead...
... The Physique leads are small profile ... active-fixation helix. With a lead body size ... tip size of 7 F, the Physique ... lead available today. Available in both straight ...
Medicine Products: